This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
RNF168-mediated ubiquitin signaling inhibits the viability of BRCA1 null cancers
Cancer Res. 2020 Jul 1;80(13) :2848-2860
PMID: 32213544 PMCID: PMC7335334 URL: https://www.ncbi.nlm.nih.gov/pubmed/32213544
AbstractBRCA1 gene mutations impair homologous recombination (HR) DNA repair, resulting in cellular senescence and embryonic lethality in mice. Therefore, BRCA1-deficient cancers require adaptations that prevent excessive genomic alterations from triggering cell death. RNF168-mediated ubiquitination of gammaH2AX at K13/15 (ub-H2AX) serves as a recruitment module for the localization of 53BP1 to DNA break sites. Here, we found multiple BRCA1 mutant cancer cell lines and primary tumors with low levels of RNF168 protein expression. Overexpression of ectopic RNF168 or a ub-H2AX fusion protein induced cell death and delayed BRCA1 mutant tumor formation. Cell death resulted from the recruitment of 53BP1 to DNA break sites and inhibition of DNA end resection. Strikingly, re-introduction of BRCA1 or 53BP1 depletion restored HR and rescued the ability of cells to maintain RNF168 and ub-H2AX overexpression. Thus, downregulation of RNF168 protein expression is a mechanism for providing BRCA1 null cancer cell lines with a residual level of HR that is essential for viability. Overall, our work identifies loss of RNF168 ubiquitin signaling as a proteomic alteration that supports BRCA1 mutant carcinogenesis. We propose that restoring RNF168-ub-H2AX signaling, potentially through inhibition of de-ubiquitinases, could represent a new therapeutic approach.
Notes1538-7445 Krais, John J ORCID: https://orcid.org/0000-0002-3916-3435 Wang, Yifan Bernhardy, Andrea J Clausen, Emma Miller, Jessica A Cai, Kathy Q Scott, Clare L Johnson, Neil Journal Article United States Cancer Res. 2020 Mar 25. pii: 0008-5472.CAN-19-3033. doi: 10.1158/0008-5472.CAN-19-3033.